Regional Phenotyping of CF and Non-CF Bronchiectasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-08

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560

Cystic Fibrosis

ACTIVE_NOT_RECRUITING

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

NCT04467957

Cystic Fibrosis

ACTIVE_NOT_RECRUITING PHASE4

Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations

NCT02606487

Cystic Fibrosis

COMPLETED

Regional Monitoring of CF Lung Disease

NCT06339593

Cystic Fibrosis

RECRUITING EARLY_PHASE1

Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI

NCT03593434

Cystic Fibrosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Specific Aim 1: Validate functional imaging markers in CF patients with normal spirometry but abnormal ventilation. The Investigators hypothesize imaging phenotype can predict lung function decline, even in CF patients with normal spirometry. The Investigators will test this hypothesis by performing annual HP 129Xe ventilation MRI in a cohort of CF patients of which a subset has normal FEV1 (≥85% predicted) at baseline.

Specific Aim 2: Determine the sensitivity and specificity of early structural remodeling in CF lung disease. The Investigator's preliminary studies show that imaging markers of structural lung remodeling can be measured via radiation-free MRI (as opposed to x-ray CT). We assess the sensitivity to identify subjects with irreversible remodeling by performing serial ultra-short UTE MRI.

In the first arm (Aims 1 \& 2) Up to 50 subjects will be recruited-approximately 25 with normal FEV1 (\>85% predicted) and 25 with mild to moderate disease. All subjects will be asked to undergo longitudinal (i.e., approximately annually) 129Xe and UTE MRI, spirometry, and lung clearance index (LCI) measurement. If possible, studies will be coordinated with clinical visits to maximize recruitment and retention. Up to 50 age and sex matched control subjects (i.e., subjects with no known cardiopulmonary disorders) may also be recruited to provide a reference data set from healthy subjects for comparison.

Healthy adults, including CCHMC employees) and children \>5 years old may be recruited as needed for MRI sequence development and validation.

In the second arm (Aim 3), 50 CF patients with bronchiectasis and 50 with non-CF bronchiectasis will be recruited from patients already undergoing clinical bronchoscopies. Before bronchoscopy, subjects will undergo UTE. BAL will be obtained from radiologically normal areas and regions with abnormalities. (Note, image-guided sampling from multiple sites is routine practice at CCHMC in patients with CF and non-CF bronchiectasis. As such, the proposed studies will not alter the sampling pattern in a clinically significant way or increase procedure time, and will thus add no patient risk.) Clinical BAL will be collected from these regions, and small aliquots (\~500 µL) will be stored separately for proteomics. The remaining fluid will be pooled and submitted for routine clinical testing, with \~500 µL reserved for pooled proteomics. The Investigators will recruit \~10 subjects/yr from both CF and non-CF groups, who will be followed annually with UTE and proteomic analysis that will be collected under Dr. Ziady's companion protocol, titled Proteomic biomarkers of CF disease and non-CF bronchiectasis to measure prognostic markers of disease-in particular of persistent bronchiectasis. For all subjects, clinical data (e.g., age, gender, CF genotype, microbiology, therapies-including CFTR modulators-and exacerbation frequency) will be captured in a REDcap database.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis Non-CF Bronchiectasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CF and Non-CF Bronchiectasis

In the first arm (Aims 1 \& 2) Up to 50 subjects will be recruited-approximately 25 with normal FEV1 (\>85% predicted) and 25 with mild to moderate disease. All subjects will be asked to undergo longitudinal (i.e., approximately annually) 129Xe and UTE MRI, spirometry, and lung clearance index (LCI) measurement.

Xenon

Intervention Type DRUG

Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, "scout" images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose.

Healthy Subjects

Up to 50 age and sex matched control subjects (i.e., subjects with no known cardiopulmonary disorders) may also be recruited to provide a reference data set from healthy subjects for comparison.

Xenon

Intervention Type DRUG

Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, "scout" images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xenon

Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, "scout" images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

129Xe

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CF Patients: Diagnosis of CF based on sweat chloride \>60 mMol/l
* Presence of two disease causing CFTR mutations, or end organ manifestations of disease.
* Age minimum 5 years.
* Care provided by the CCHMC CF Care Center or other regional CF Care Centers if required to achieve recruitment goals.

* Subjects 5 years of age and older with no known history of cardiopulmonary disease.

Exclusion Criteria

* Patients meeting standard MRI exclusions criteria (non-MRI-compatible metal implants, claustrophobia, etc.)
* Pregnancy or lactation.

* Patients meeting standard MRI exclusions criteria (non-MRI-compatible metal implants, claustrophobia, etc.)
* Pregnancy or lactation.

Minimum Eligible Age

5 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes